Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.
Janne PA, von Pawel J, Cohen RB, Crino L, Butts CA, Olson SS, Eiseman IA, Chiappori AA, Yeap BY, Lenehan PF, Dasse K, Sheeran M, Bonomi PD
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer
Journal of Clinical Oncology (2007) 25:3936-3944.
Purpose To evaluate the efficacy of the pan-ERBB inhibitor, CI- 1033, in platinum- refractory or recurrent advanced-stage non-small-cell lung cancer ( NSCLC). Patients and Methods This open-label, randomized phase II trial evaluated CI- 1033 in patients with advanced- stage NSCLC who experienced treatment failure after or were refractory to platinum- based chemotherapy. Three oral CI- 1033 doses were evaluated in 21- day dosing cycles: 50 mg daily for 21 consecutive days, 150 mg daily for 21 consecutive days, and 450 mg daily for 14 consecutive days followed by 7 days of no treatment. The primary efficacy end point was the 1- year survival rate. Results One hundred sixty-six patients were randomly assigned to treatment. Baseline patient demographics were well balanced. The most common drug- related adverse events were rash and diarrhea. The 450- mg arm ( 14 days on/ 7 days off) was closed early due to an excessive rate of adverse events. The 1- year survival rates were 29%, 26%, and 29%, respectively, in the three arms. The response rates were 2%, 2%, and 4%, and stable disease was confirmed in 16%, 23%, and 18% of patients, respectively, in the three study arms. Exploratory analyses demonstrated a prolonged survival in patients who developed a rash and in those with baseline tumor ERBB-2 expression. Conclusion CI- 1033 had modest activity in unselected NSCLC patients but did not meet its primary end point. Future studies should focus on identifying methods of patient selection.
Publication Date: 2007-09-01.
Last updated on Saturday, August 22, 2020